Blackrock Neurotech
- Industry
- Medical Device
- Founded Year
- 2008
- Headquarters
- Salt Lake City, Utah, USA
- Employee Count
- 198
Key People
- Marcus Gerhardt - Co-Founder & CEO
- Florian Solzbacher - Co-Founder & CSO
- Jeff C. Jensen - CTO
- Nathan Smith - CFO
- Raj Bhandari - VP, Development Electrode
- Kristen McIntosh - VP, Business Operations
- Sandeep Negi - Director of Research Electrodes
- Bryan Satterfield - Director, Operations
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in MedTech and related fields.
The leadership includes individuals like Marcus Gerhardt, who has a history of entrepreneurship in innovative technologies, and Dr. Florian Solzbacher, a professor and co-founder with significant contributions to neurotechnology. Their combined expertise enhances the company's strategic direction and operational execution.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's BCI technology addresses critical needs for individuals with neurological disorders, paralysis, or limb loss.
Blackrock Neurotech's BCI systems offer solutions for restoring function and independence to patients with severe physical impairments. This addresses a substantial and growing patient population seeking effective interventions.
- Competition
-
Aspect: First mover
Summary: Blackrock Neurotech is a pioneer in the BCI field, with a strong position in the market.
As one of the first companies to develop implantable BCI technology, Blackrock Neurotech has established a robust presence, with its devices used in numerous clinical studies and by over 40 individuals to date.
- Technical Challenge
-
Aspect: Very Complex
Summary: Developing implantable BCI systems involves significant technical complexities.
The creation of safe, effective, and reliable implantable BCIs requires overcoming substantial technical hurdles, including biocompatibility, signal processing, and long-term stability, which can impact development timelines and costs.
- Patent
-
Aspect: Very Strong
Summary: The company holds a robust portfolio of patents in neurotechnology.
Blackrock Neurotech's extensive patents cover critical aspects of BCI technology, offering protection against competitors and potential licensing opportunities, thereby strengthening its market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With investments from entities like re.Mind Capital and individuals such as Peter Thiel, Blackrock Neurotech has the financial resources to advance its technology and expand its market reach.
- Regulatory
-
Aspect: Running FIH
Summary: The company is conducting first-in-human trials for its BCI systems.
Engaging in first-in-human trials indicates that Blackrock Neurotech's technology is advancing through the necessary regulatory pathways, bringing it closer to potential market approval and commercialization.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.25
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Brain-Computer Interfaces
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.79 |
| 3 | 1.84 |
| 4 | 3.68 |
| 5 | 5.25 |
Key Takeaway
Blackrock Neurotech is a pioneering company in the BCI field, leveraging a strong team, robust patent portfolio, and significant funding to address critical clinical needs, positioning itself for substantial market impact.